VKTX
Viking Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +2.6% · netto nieuwe posities 0.0% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 24.17K | $674,494 | n/a | −1 |
| Q2 2026 | 108 | +6 | 57.61M | $2.25B | +9 | −4 |
| Q1 2026 | 106 | -1 | 56.45M | $1.88B | +7 | −8 |
| Q4 2025 | 106 | +1 | 58.95M | $2.07B | +2 | −1 |
| Q3 2025 | 16 | -1 | 41.62M | $1.09B | +2 | −4 |
| Q2 2025 | 15 | 0 | 36.99M | $980.19M | +2 | −2 |
| Q1 2025 | 12 | +3 | 10.64M | $256.98M | +3 | n/a |
| Q4 2024 | 9 | -3 | 10.39M | $418.15M | n/a | −3 |
| Q3 2024 | 11 | -1 | 6.74M | $426.33M | n/a | −1 |
| Q2 2024 | 12 | n/a | 5.57M | $295.04M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 10.16M | n/a | $269.31M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | Fidelity (FMR) ✦ | 9.82M | n/a | $260.28M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | BlackRock ✦ (passief) | 5.44M | n/a | $144.09M | 0.0% | n/c | 1 | SEC ↗ ×19 |
| 4 | State Street Global Advisors ✦ (passief) | 3.78M | -6.9% | $100.06M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passief) | 1.92M | -3.1% | $50.98M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passief) | 1.77M | +14.4% | $46.85M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.31M | +2406.6% | $34.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 941.94K | +272.8% | $24.96M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 872.98K | -47.1% | $23.13M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Duquesne Family Office ✦ | 549.29K | Nieuw | $14.56M | 0.4% | New | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 205.47K | -37.0% | $5.45M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | T. Rowe Price ✦ | 78.18K | +11.5% | $2.07M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 64.73K | -55.4% | $1.72M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
| 14 | Point72 Asset Management ✦ | 39.93K | Nieuw | $1.06M | 0.0% | New | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 32.70K | -90.0% | $866,550 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Duquesne Family Office | $14.56M | 0.4% |
| Point72 Asset Management | $1.06M | 0.0% |
Verlaten
| Marshall Wace | $5.02M | was 0.0% |
| Gotham Asset Management | $591,675 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 9.80K aandelen, $318 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.